ResearcherUniversity of North Carolina at CharlotteNo recent work listed
Andrea M. Murphy
Matched on OpenAlex author ID A5018546933. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2012: 1 paper · 2013: 4 papers
Papers 5
- The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. Co-author DOI 10.1002/jso.23316↗
- Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Co-author DOI 10.1016/j.virol.2012.11.014↗
- Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma. Co-author DOI 10.1128/jvi.01412-13↗
- Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal Adenocarcinoma Co-author DOI 10.1128/jvi.02979-12↗
- Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. Co-author DOI 10.1128/jvi.05640-11↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Pinku Mukherjee · 5 shared papers, 2012–2013 · strength 0.19
- Paper Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. DOI 10.1016/j.virol.2012.11.014↗
- Paper Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal Adenocarcinoma DOI 10.1128/jvi.02979-12↗
- Paper Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenoc… DOI 10.1128/jvi.01412-13↗
- Valery Z. Grdzelishvili · 5 shared papers, 2012–2013 · strength 0.19
- Paper Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. DOI 10.1016/j.virol.2012.11.014↗
- Paper Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal Adenocarcinoma DOI 10.1128/jvi.02979-12↗
- Paper Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenoc… DOI 10.1128/jvi.01412-13↗
- Megan J Moerdyk-Schauwecker · 4 shared papers, 2012–2013 · strength 0.15
- Paper Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. DOI 10.1016/j.virol.2012.11.014↗
- Paper Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal Adenocarcinoma DOI 10.1128/jvi.02979-12↗
- Paper Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenoc… DOI 10.1128/jvi.01412-13↗
- Dahlia M. Besmer · 4 shared papers, 2012–2013 · strength 0.14
- Paper Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal Adenocarcinoma DOI 10.1128/jvi.02979-12↗
- Paper Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenoc… DOI 10.1128/jvi.01412-13↗
- Paper Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. DOI 10.1128/jvi.05640-11↗
- Eric L. Hastie · 2 shared papers, 2013 · strength 0.08
- Paper Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. DOI 10.1016/j.virol.2012.11.014↗
- Paper Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenoc… DOI 10.1128/jvi.01412-13↗
- Jennifer M. Curry · 2 shared papers, 2013 · strength 0.07
- Paper Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenoc… DOI 10.1128/jvi.01412-13↗
- Paper The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreati… DOI 10.1002/jso.23316↗
- Lopamudra Das Roy · 1 shared paper, 2013 · strength 0.03
- John B. Martinie · 1 shared paper, 2013 · strength 0.03
- David A. Iannitti · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.